![]() |
市場調查報告書
商品編碼
1402481
2030 年亞太地區深腦模擬市場預測 - 區域分析 - 按產品、應用和最終用戶Asia Pacific Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User |
亞太地區深腦模擬市場預計將從2022年的9,835萬美元成長到2030年的1.8804億美元。預計2022年至2030年CAGR為8.4%。
深部腦部刺激的技術進步和批准推動亞太地區深部腦部模擬市場
機器人植入、多目標刺激、改進的微電極設計、可充電脈衝產生器以及個人化、有針對性的程式都是深部腦部刺激 (DBS) 領域的技術進步。由於這些進步,與傳統方法相比,DBS 設備在帕金森氏症患者中顯示出更少的副作用、更高的療效和症狀緩解。 Abbott 的 Infinity 腦深部刺激系統是一種技術先進的新型 DBS,可幫助患者控制症狀。它是第一個無線 iOS 軟體 DBS 行動平台,可提供高效、個人化的治療管理,並降低副作用風險。根據 2020 年 2 月發布的 MGM Healthcare 新聞稿,泰米爾納德邦 MGM Healthcare 首次針對強迫症 (OCD) 進行了深部腦部刺激 (DBS)。因此,DBS 的技術進步預計將在預測期內為亞太地區深部腦部刺激市場創造機會。
亞太地區深腦模擬市場概況
中國是世界上老年人口最多的國家。根據《柳葉刀》發表的題為「中國人口老化:危機還是機會?」的研究報告。 2019年,中國60歲以上人口約2.54億人。到 2040 年,這一數字預計將增至 4.02 億,約佔總人口的 28%。隨著非傳染性疾病的風險和負擔隨著對衛生和社會保健系統的需求的增加而增加,這些變化對該國的公共衛生產生了深遠的影響。帕金森氏症(PD)是我國常見的神經退化性疾病。根據《中國日報》報道,截至 2023 年 2 月,中國約有 400 萬名帕金森氏症患者,65 歲以上族群中約有 1.7% 被診斷出患有此疾病。根據《健康、人口和營養雜誌》上討論的一項研究,中國患有阿茲海默症的人數約為 600 萬,其中 65 歲、75 歲和 85 歲人群的癡呆率為 5%,分別為11.5% 和30%。丘腦底核 (STN) 的深部腦部刺激 (DBS) 可有效治療巴金森氏症 (PD)。隨著DBS硬體的進步,研究人員開發了多種新穎的程式技術,其中遠端程式設計在中國已廣泛應用。自2018年以來,我們一直使用PINS產品(中國北京PINS醫療有限公司)為患有PD的患者進行遠端編程。對於患有晚期帕金森氏症(超過 15 年)的患者,DBS 被認為是一種高效的治療選擇。然而,與任何其他已開發國家不同,如果無法報銷,DBS 仍然會給患者帶來巨大的經濟負擔。在中國,手術費用主要由患者的健康保險承擔,但 DBS 硬體的費用僅涵蓋部分,這可能會阻礙該國市場的成長。
亞太地區深腦模擬市場營收及 2030 年預測(百萬美元)
亞太地區深腦模擬市場區隔
亞太地區深腦模擬市場分為產品、應用、最終用戶和國家。
根據產品,亞太地區深部腦部模擬市場分為單通道深部腦部刺激器、雙通道深部腦部刺激器以及軟體和配件。 2022年,雙通道深部腦部刺激器細分市場在亞太深部腦部模擬市場中佔據最大佔有率。
根據應用,亞太地區深部腦部模擬市場分為帕金森氏症、震顫、肌張力失調、癲癇、阿茲海默症等。 2022年,帕金森氏症領域在亞太深部腦部模擬市場中佔據最大佔有率。
根據最終用戶,亞太地區深部腦部模擬市場分為醫院、神經科診所、門診手術中心等。 2022年,醫院領域在亞太深部腦部模擬市場中佔據最大佔有率。
依國家/地區分類,亞太地區深度腦模擬市場分為中國、日本、印度、韓國、澳洲和亞太地區其他地區。 2022年,中國市場在亞太深腦模擬市場中佔據最大佔有率。
Abbott Laboratories、北京品思醫療有限公司、波士頓科學公司、Medtronic Plc 和 SceneRay Co Ltd 是亞太地區深腦模擬市場的一些領先公司。
The Asia Pacific deep brain simulation market is expected to grow from US$ 98.35 million in 2022 to US$ 188.04 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.
Technological Advancements and Approvals in Deep Brain Stimulation Drive Asia Pacific Deep Brain Simulation Market
Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects. According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the Asia Pacific deep brain stimulation market during the forecast period.
Asia Pacific Deep Brain Simulation Market Overview
China is home to the world's largest population of older adults. According to a study published in The Lancet titled "China's Aging Population: Crisis or Opportunity?" in 2019, people in China aged 60 or older were ~254 million. By 2040, that number is expected to rise to 402 million, ~28% of the population. These changes have profound public health implications in the country as the risk and burden of noncommunicable diseases increase along with the demand for health and social care systems. Parkinson's disease (PD) is a common neurodegenerative disease in the country. According to ChinaDaily, there were approximately 4 million Parkinson's patients in China as of February 2023, and ~1.7% of people over 65 years have been diagnosed with the disease. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in the treatment of Parkinson's disease (PD). With advancements in DBS hardware, researchers have developed several novel programming technologies, of which remote programming is widely used in China. Since 2018, we have been performing remote programming for patients suffering from PD using PINS products (PINS Medical, Ltd., Beijing, China). For patients with advanced Parkinson's disease (over a 15-year time horizon), DBS is considered to be a highly effective treatment option. However, DBS remains a significant economic burden on the patient when not reimbursed, unlike in any other developed country. In China, the surgery cost is mainly covered by the patient's health insurance, but the cost of DBS hardware is only partially covered, which can hamper the growth of the market in the country.
Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Deep Brain Simulation Market Segmentation
The Asia Pacific deep brain simulation market is segmented into product, application, end user, and country.
Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson's disease, tremor, dystonia, epilepsy, Alzheimer's disease, and others. In 2022, the Parkinson's disease segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. In 2022, China segment registered the largest share in the Asia Pacific deep brain simulation market.
Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd are some of the leading companies operating in the Asia Pacific deep brain simulation market.